A little over four years ago, biotechnology giant Amgen retreated from neuroscience research, halting much of its work developing treatments for diseases of the brain and trimming associated staff.
Amgen’s pivot proved a boon for a small startup that was then just getting started in the big drugmaker’s backyard. Latigo Biotherapeutics, which, like Amgen, is based in Thousand Oaks, California, quickly hired some of those former Amgen scientists to jump-start its own neuroscience plans.
